MD1716C2 - Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine - Google Patents

Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine

Info

Publication number
MD1716C2
MD1716C2 MD97-0254A MD970254A MD1716C2 MD 1716 C2 MD1716 C2 MD 1716C2 MD 970254 A MD970254 A MD 970254A MD 1716 C2 MD1716 C2 MD 1716C2
Authority
MD
Moldova
Prior art keywords
treatment
melatonin
benzodiazepine
benzodiazepinic
dependence
Prior art date
Application number
MD97-0254A
Other languages
English (en)
Romanian (ro)
Russian (ru)
Other versions
MD970254A (en
MD1716B2 (en
Inventor
Nava Zisapel
Original Assignee
Neurim Pharmaceuticals (1991) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,535 external-priority patent/US6469044B1/en
Application filed by Neurim Pharmaceuticals (1991) Ltd. filed Critical Neurim Pharmaceuticals (1991) Ltd.
Publication of MD970254A publication Critical patent/MD970254A/xx
Publication of MD1716B2 publication Critical patent/MD1716B2/xx
Publication of MD1716C2 publication Critical patent/MD1716C2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MD97-0254A 1995-02-01 1996-01-29 Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine MD1716C2 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
EP95303853A EP0724878B1 (en) 1995-02-01 1995-06-06 Use of melatonin for treating patients suffering from drug dependencies
PCT/IB1996/000082 WO1996023496A1 (en) 1995-02-01 1996-01-29 Use of melatonin for treating patients suffering from drug addiction

Publications (3)

Publication Number Publication Date
MD970254A MD970254A (en) 1999-05-31
MD1716B2 MD1716B2 (en) 2001-08-31
MD1716C2 true MD1716C2 (ro) 2002-02-28

Family

ID=26140195

Family Applications (1)

Application Number Title Priority Date Filing Date
MD97-0254A MD1716C2 (ro) 1995-02-01 1996-01-29 Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine

Country Status (22)

Country Link
JP (1) JP4516159B2 (lv)
CN (1) CN1083263C (lv)
AT (1) AT408188B (lv)
AU (1) AU695366B2 (lv)
BG (1) BG62876B1 (lv)
BR (1) BR9607169A (lv)
CZ (1) CZ291349B6 (lv)
DK (1) DK176081B1 (lv)
EE (1) EE03384B1 (lv)
FI (1) FI119586B (lv)
IS (1) IS1980B (lv)
LU (1) LU90118B1 (lv)
LV (1) LV11940B (lv)
MD (1) MD1716C2 (lv)
NO (1) NO312814B1 (lv)
NZ (1) NZ298878A (lv)
PL (1) PL183148B1 (lv)
SI (1) SI9620022A (lv)
SK (1) SK284521B6 (lv)
TR (1) TR199700723T1 (lv)
TW (1) TW483757B (lv)
WO (1) WO1996023496A1 (lv)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60034373T2 (de) 2000-01-05 2007-12-20 Neurim Pharmaceuticals (1991) Ltd. Methode und zusammensetzung zur behandlung von resistenz gegen antihypertensiva und verwandten zuständen
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
BR112014018429A8 (pt) 2012-01-26 2017-07-11 Vanda Pharmaceuticals Inc Método para tratar um paciente que sofre de não-24, e, método para o tratamento crônico de não-24 em uma pessoa que está totalmente cega
AU2013361459A1 (en) 2012-12-18 2015-07-02 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
JP6830156B2 (ja) * 2016-10-31 2021-02-17 ニューリム・ファーマシューティカルズ・リミテッドＮｅｕｒｉｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ． メラトニンミニタブレットおよびその製造方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0513702A2 (en) * 1991-05-13 1992-11-19 I.F.L.O. ISTITUTO FARMACOLOGICO LOMBARDO S.A.S. di Giorgio & Aldo Laguzzi & C. Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication
EP0518468A1 (en) * 1991-05-09 1992-12-16 Neurim Pharmaceuticals (1991) Limited Melatonin containing compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0518468A1 (en) * 1991-05-09 1992-12-16 Neurim Pharmaceuticals (1991) Limited Melatonin containing compositions
EP0513702A2 (en) * 1991-05-13 1992-11-19 I.F.L.O. ISTITUTO FARMACOLOGICO LOMBARDO S.A.S. di Giorgio & Aldo Laguzzi & C. Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication

Also Published As

Publication number Publication date
IS1980B (is) 2005-01-14
NO973531D0 (no) 1997-07-31
LV11940B (lv) 1998-05-20
CZ291349B6 (cs) 2003-02-12
CN1172431A (zh) 1998-02-04
LU90118B1 (fr) 1997-11-13
FI973185A (fi) 1997-09-30
LV11940A (lv) 1998-01-20
DK176081B1 (da) 2006-04-18
AT408188B (de) 2001-09-25
MD970254A (en) 1999-05-31
SI9620022A (sl) 1998-10-31
JP4516159B2 (ja) 2010-08-04
CZ240597A3 (cs) 1998-01-14
CN1083263C (zh) 2002-04-24
SK284521B6 (sk) 2005-05-05
PL183148B1 (pl) 2002-05-31
SK103097A3 (en) 1998-01-14
NO312814B1 (no) 2002-07-08
IS4532A (is) 1997-07-25
MD1716B2 (en) 2001-08-31
ATA901396A (de) 2001-02-15
JPH10513177A (ja) 1998-12-15
MX9705856A (es) 1998-07-31
AU4457496A (en) 1996-08-21
NZ298878A (en) 1999-05-28
TW483757B (en) 2002-04-21
BG62876B1 (bg) 2000-10-31
DK89697A (da) 1997-07-30
TR199700723T1 (xx) 1998-02-21
WO1996023496A1 (en) 1996-08-08
BR9607169A (pt) 1997-11-11
PL321630A1 (en) 1997-12-08
BG101803A (en) 1998-04-30
EE9700166A (et) 1998-02-16
NO973531L (no) 1997-09-30
AU695366B2 (en) 1998-08-13
FI973185A0 (fi) 1997-07-31
FI119586B (fi) 2009-01-15
EE03384B1 (et) 2001-04-16

Similar Documents

Publication Publication Date Title
ES2165910T3 (es) Administracion nasal y ocular de cetamina para el tratamiento del dolor y para la desintoxicacion.
PT913156E (pt) Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
PT613371E (pt) Nova combinacao de formoterol e budesonido
NO306377B1 (no) Doseform for avgivelse av et medikament
HU9301978D0 (en) Application of complementary inhibitors in medical preparatives used for treatment of inflammatory diseases of intestines and skin
HUT77380A (hu) Kombinált gyógyszerkészítmény alkalmazása sclerosis multiplex (MS) és más demielizáló állapotok kezelésére
CZ176495A3 (en) The use of riluzol for preparing a medicament suitable for treating parkinson's disease and parkinson's syndromes
MD1716C2 (ro) Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine
BG106171A (en) Compositions and uses of et743 for treating cancer
ES2139842T3 (es) Uso de la melatonina para tratar a pacientes que sufren drogodependencia.
FI973023A0 (fi) Liikakasvusairauksien yhdistetty terapeuttinen hoito
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
EP0147185A3 (en) Therapeutic use of cytidyl disphosphocholine to increase neuronal acetylcholine
NZ307601A (en) Use of a pharmaceutically acceptable oxalate derivative in the manufacture of a medicament for the treatment of skin conditions
AU6432899A (en) Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
SE9000207D0 (sv) Laekemedel samt anvaendningen av detsamma
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
SE9101341D0 (sv) New medicinal use
UA29589A (uk) Бронхолітичний засіб "інгапін"
Hole et al. Special depression treatment wards in the Federal Republic of Germany: A survey.
HUP9900627A2 (hu) Melatonin alkalmazása gyógyszerfüggőségben szenvedő páciensek kezelésére alkalmas gyógyszerkészítmények előállítására
EP1264601A3 (en) Treatment of a coronary condition by delivery of therapeutics to the pericardial space
Cheng Benefits of combination therapy confirmed

Legal Events

Date Code Title Description
PD99 Pending application
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees